Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera

Mathias Kees; Franz Wiesbauer; Bettina Gisslinger; Renate Wagner; Medhat Shehata; Heinz Gisslinger

doi:10.1160/TH04-06-0394

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 93(01): 70-75
DOI: 10.1160/TH04-06-0394

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera

Mathias Kees

¹Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria

,

Franz Wiesbauer

²Department of Internal Medicine II, Division of Cardiology, Medical University Vienna, Vienna, Austria

,

Bettina Gisslinger

¹Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria

,

Renate Wagner

¹Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria

,

Medhat Shehata

¹Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria

,

Heinz Gisslinger

¹Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria

› Author Affiliations

Abstract

Full Text

PDF Download

Keywords

Osteoprotegerin - polycythemia vera - thrombosis - bleeding - vascular complications

References

References
1 Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-64.
2 Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-90.
3 Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2: 1219-22.
4 Ruggeri M, Gisslinger H, Tosetto A. et al Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002; 71: 1-6.
5 Gisslinger H, Rodeghiero F, Ruggeri M. et al Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol 1999; 105: 551-5.
6 Michiels JJ. Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism. Semin Thromb Hemost 1997; 23: 335-8.
7 Neunteufl T, Heher S, Stefenelli T. et al Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol 2001; 115: 354-9.
8 Falanga A, Marchetti M, Evangelista V. et al Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-6.
9 Cines DB, Pollak ES, Buck CA. et al Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
10 Jono S, Ikari Y, Shioi A. et al Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-4.
11 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-7.
12 Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-53.
13 Simonet WS, Lacey DL, Dunstan CR. et al Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
14 Lacey DL, Timms E, Tan HL. et al Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
15 Fata JE, Kong YY, Li J. et al The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103: 41-50.
16 Bucay N, Sarosi I, Dunstan CR. et al osteoprotegerin- deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8.
17 Kim HH, Shin HS, Kwak HJ. et al RANKL regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. FASEB J 2003; 17: 2163-5.
18 Collin-Osdoby P, Rothe L, Anderson F. et al Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276: 20659-72.
19 Zhang J, Fu M, Myles D et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521: 180-4.
20 Tan KB, Harrop J, Reddy M. et al Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997; 204: 35-46.
21 Schoppet M, Sattler AM, Schaefer JR. et al Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-8.
22 Knudsen ST, Foss CH, Poulsen PL. et al Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003; 149: 39-42.
23 Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombo-cythemia. Semin Hematol 1999; 36: 9-13.
24 Landolfi R, Marchioli R, Kutti J. et al Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-24.
25 Rothman K, Greenland S. Modern Epidemiology Philadelphia: Lippincott Williams & Wilkins; 1998: 255-7.
26 Clayton D, Hills M. Statistical Models in Epidemiology. Oxford: Oxford University Press; 1993
27 Chagraoui H, Tulliez M, Smayra T. et al Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 2003; 101: 2983-9.
28 Chagraoui H, Sabri S, Capron C. et al Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. Exp Hematol 2003; 31: 1081-8.
29 Malyankar UM, Scatena M, Suchland KL. et al Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000; 275: 20959-62.